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Background/aim: To investigate the effect of dietary salt restriction on blood pressure levels, total sodium removal, and hydration status
of peritoneal dialysis (PD) patients.
Materials and methods: Thirty-one stable PD patients who consulted a renal dietitian monthly for dietary recommendations, including
restricted salt intake <5 g/day, and education about hypertension and hypervolemia were included in this study. Baseline and third
month clinical and laboratory findings, bioelectrical impedance analysis results, and urinary and peritoneal sodium removal values
were recorded.
Results: The mean age of the patients was 47.6 years and the mean time on PD was 39.6 months. The mean total sodium removal
decreased slightly from 139.4 ± 69.1 to 136.2 ± 64.8 mmol/day (P > 0.05) for the whole sample, and from 164.3 ± 70.9 to 154.2 ± 72.3
mmol/day (P > 0.05) for the hypertensive subgroup (n: 17). Systolic blood pressure (from 134.3 ± 20.1 to 127.2 ± 19.5 mmHg, P: 0.01),
diastolic blood pressure (from 83.2 ± 12.0 to 77.4 ± 10.5 mmHg, P: 0.01) and total body water (from 39.2 ± 10.9 to 38.3 ± 9.3 L, P: 0.04)
decreased significantly.
Conclusion: We demonstrated that even a little reduction in daily dietary sodium intake caused significant decreases in blood pressure
levels and fluid overload.
Key words: Bioimpedance analysis, hypertension, hypervolemia, peritoneal sodium removal, salt intake, salt restriction

1. Introduction
Cardiovascular disease is the most important cause of
morbidity and mortality in peritoneal dialysis (PD)
patients with end stage renal disease (1,2). In common
with the general population, hypertension is the leading
factor for cardiovascular diseases and is rather common
in PD patients (3). Due to some hemodynamic advantages
of PD over hemodialysis, older studies suggest that control
of hypertension is easier with PD than hemodialysis
(4). However, later studies with larger sample sizes
demonstrated that hypertension remains an important
problem for PD patients (1,5).
Chronic fluid overload is regarded as the main cause
of hypertension in PD patients (6). A recently published
EuroBCM study, the first large multicenter study of
hydration status in European PD patients, also underlined
the fact that fluid overload is a frequent problem in this
group of patients (25% of 639 PD patients were severely
fluid overloaded) and relying only on clinical parameters
for its assessment might be misleading (7). The survival
* Correspondence: salihinal@yahoo.com
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of PD patients was reported to be directly correlated to
the amount of water that could be excreted per 24 h (8,9).
Therefore, the authors mainly focused on the adequacy
of ultrafiltration and residual renal function (9,10).
Interestingly, excessive salt intake, which is the primary
driving force for fluid overload, is generally neglected.
Currently, it is underlined that ‘salt balance’ should also be
used as an adequacy parameter and a predictor of outcome
as well as fluid balance in PD patients (10).
Regarding the fact that salt balance can be improved
mainly by reducing salt intake, we aimed to investigate
the effect of dietary salt restriction on the control of blood
pressure levels and the total sodium removal in patients
on PD.
2. Materials and methods
2.1. Patient selection and classification
This study examined 50 clinically stable patients who had
been undergoing PD therapy for more than 6 months
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at Gazi University Hospital, Ankara. Patients who were
18 years of age or older and who had been visiting our
outpatient clinic monthly were included in the study.
Exclusion criteria were a history of peritonitis in the
previous 3 months, history of limb amputation, presence
of a pacemaker or defibrillator, and inability to provide
informed consent. During the study period (from May to
August 2010) 1 patient died, 1 had renal transplantation,
and 17 patients either refused to be on such a strict diet or
quit the study during follow-up. The remaining 31 patients
were included in the final evaluation. Sodium concentration
in PD solutions of the study population was 132 mmol/L.
Patients consulted a renal dietitian monthly for dietary
recommendations including restricted salt intake <5 g/
day according to the recommendations of European Best
Practice Guidelines on nutrition (11). We also educated
all patients about hypertension and hypervolemia, in
order to increase their compliance to antihypertensive
therapy and dietary recommendations. At the beginning
and during the third month of follow-up, clinical and
laboratory findings and bioelectrical impedance analysis
results were recorded. The study was conducted according
to the Helsinki Declaration and approved by the Ethics
Committee of Gazi University School of Medicine. All
patients gave their informed consent to participate in the
study.
2.2. Blood pressure measurements and bioimpedance
analysis
Brachial blood pressure was measured 3 times in every
patient and average values were accepted as systolic and
diastolic office blood pressures. Measurements were
performed with a mercury sphygmomanometer in a
sitting position after 10 min rest. Patients who usually
took antihypertensive medication were asked to take their
pills before the visit, and the number of antihypertensive
drugs taken was also recorded. During clinical visits the
antihypertensive treatment of each patient was reevaluated
and, if appropriate, the number of drugs was decreased.
Diuretics were neither started nor stopped in the followup period. Hypertension was defined according to the
World Health Organization/International Society of
Hypertension criteria (12) as systolic blood pressure (SBP)
≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90
mmHg using office blood pressure measurements, or being
on current treatment with an antihypertensive drug. Our
target blood pressure levels for the patients were below
135 mmHg for systolic and below 85 mmHg for diastolic
values, according to the criteria of similar studies (13).
Bioelectrical impedance analysis (BIA) was performed
with a Quadscan 4000 (Body Stat, UK) multifrequency
bioimpedance spectrum analyzer in order to determine
the volume status of the patients. Measurements were
performed in the right calf at 4 frequencies (5, 50, 100,

and 200 kHz) in the supine position after patients had
emptied their dialysis solutions. Extracellular water
(ECW), intracellular water (ICW), and total body water
(TBW) contents were measured by BIA. Percentage ECW
and ICW values were calculated by dividing ECW or ICW
over TBW.
2.3. Evaluation of fluid and sodium removal
At the beginning and during the third month of follow-up,
plasma sodium concentration, urinary sodium removal
(USR), and peritoneal sodium removal (PSR) values were
calculated for all patients. USR was the product of 24-h
urine volume (L) multiplied by the sodium concentration
(mmol/L) in mixed urine. PSR was the value of sodium
content in total instilled dialysates subtracted from the
sodium content in drained dialysates. Total sodium
removal (TSR) was the sum of USR and PSR. Daily urine
output and ultrafiltration of the patients were recorded
and total fluid removal (TFR) was calculated as the sum
of these 2 parameters. Plasma, dialysate, and urine sodium
concentrations were measured by indirect ionometry. Total
body sodium load was the product of ECW multiplied by
plasma sodium concentration (PNa).
2.4. Statistical analysis
Statistical calculations were performed using the Statistical
Package for the Social Sciences (SPSS version 13.0).
Significance was defined as a P value less than 0.05. Data
are shown as mean ± SD or as percentages. Standard
descriptive statistics and paired sample t-test were used
where appropriate.
3. Results
The average age of the total 31 PD patients was 47.6 years
and the average time on PD was 39.6 months. Fifteen
out of 31 were females and 16.1% of the patients were
diabetics. Seventy-four percent of the patients (23/31) had
the diagnosis of hypertension, and 17 out of 31 patients
(54.8%) had blood pressures above the target levels at
the first visit. Twenty-two out of 31 patients had a daily
urine output more than 100 mL per day and they were
using furosemide. The mean office systolic and diastolic
blood pressures of the patients were recorded as 134.3 ±
20.1 and 83.2 ± 12.0 mmHg, respectively. The clinical and
demographic characteristics of the study population are
shown in Table 1.
After 3 months of salt restriction, the mean TSR
level decreased from 139.4 ± 69.1 mmol/day to 136.2 ±
64.8 mmol/day (P > 0.05). However, the mean SBP and
DBP levels decreased from 134.3 ± 20.1 mmHg to 127.2
± 19.5 (P: 0.01) and from 83.2 ± 12.0 mmHg to 77.4 ±
10.5 mmHg (P: 0.01), respectively. Moreover, mean TBW
decreased from 39.2 ± 10.9 L to 38.3 ± 9.3 L (P: 0.04) and
mean plasma sodium concentration decreased from 137.3
± 4.4 mmol/L to135.1 ± 3.9 mmol/L (P: 0.01). The number
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Table 1. Demographic and clinical parameters of the study group.
Study group (n: 31)
Age (year)

47.6 ± 14.9

Sex (M/F)

16/15

BMI (kg/m²)

26.1 ± 4.3

Time on PD (months)

39.6 ± 26.5

Diabetics (%)

16.1% (5 / 31)

Hypertensives (%)

74.2% (23 / 31)

Urine amount (mL/day)

708.1 ± 583.2

APD/CAPD

15/16

SBP (mmHg)

134.3 ± 20.1

DBP (mmHg)

83.2 ± 12.0

Smokers (%)

16.1% (5/31)

PD: Peritoneal Dialysis, BMI: Body mass index, M: Male, F: Female, APD: Automated
peritoneal dialysis, CAPD: Continuous ambulatory peritoneal dialysis, SBP: Systolic
blood pressure, DBP: Diastolic blood pressure

of antihypertensive medications per day decreased
slightly, but was not statistically significant (1.55 ± 1.23
vs. 1.48 ± 1.15, P > 0.05). The percentage of icodextrin
usage did not change significantly between the first and
the last visits (67.7% vs. 70.9%, P > 0.05). The percentage
of erythropoietin stimulating agent (ESA) usage was also
similar between the first and the last visits (54.8% vs.
61.2%, P > 0.05). A comparison of body fluid status and
sodium removal rates of the total study population is
shown in Table 2.
According to our target blood pressure values (<135
mmHg for SBP and <85 mmHg for DBP) 17 out of
31 patients (54.8%) were above the target levels at the
first visit. The remaining 14 patients were either not
hypertensive at all (n: 8) or their blood pressure levels
were under control with antihypertensive medications (n:
6). Daily salt consumption, reflected from average TSR
values, was calculated as approximately 8 g/day for the
total group and 9.1 g/day for the hypertensive PD patient
subgroup. When the subgroup of 17 hypertensive patients
was taken into consideration, in terms of TSR level there
was no significant difference between the 2 visits (164.3
± 70.9 mmol/day to 154.2 ± 72.3 mmol/day, P: NS).
However, in addition to SBP, DBP, and TBW values and
plasma sodium concentration values the decrease in terms
of mean ECW in liters also reached statistical significance
in this hypertensive subgroup (see Table 3).
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4. Discussion
In the present study, we demonstrated that total body
water and blood pressure levels could be reduced
significantly by the education of patients about therapeutic
compliance, and reducing salt and fluid consumption with
monthly dietary consultations. The patients in our study
were actually quite resistant to dietary recommendations
about salt restriction. However, even a small reduction in
daily dietary sodium intake, which was reflected by daily
total sodium removal, resulted in a significant reduction
in blood pressure levels and fluid overload. Additionally,
education about hypervolemia and hypertension alongside
dietary recommendations might have influenced patients’
compliance in terms of antihypertensive drug use and water
consumption, which might have eventually contributed to
better blood pressure control.
The prevalence of hypertension in PD patients was
reported to be 82% in a single center study and, despite
the use of antihypertensive drugs, 73% of them remained
having uncontrolled hypertension according to ambulatory
blood pressure measurements (13). Another study, from
Italy, also reported the prevalence of hypertension at 88%
in 504 PD patients (5). In Turkey, according to the data
of the renal registry, the prevalence of hypertension was
clearly higher in PD patients (57.5%) than in hemodialysis
patients (34.9%) (14). Consistent with these data, the
frequency of hypertension was 74% among our study
population.
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Table 2. Comparison of body fluid status, blood pressure, sodium removal, and plasma sodium concentrations
of the study group (n: 31) between the first and last visits.
First visit

Last visit

P

ECW (L)

17.5 ± 4.1

17.4 ± 3.7

NS

ECW (%)

24.2 ± 2.3

23.2 ± 3.3

NS

ICW (L)

21.1 ± 6.0

21.0 ± 5.6

NS

ICW (%)

29.2 ± 3.7

28.2 ± 4.4

NS

TBW (L)

39.2 ± 10.9

38.3 ± 9.3

0.04

SBP (mmHg)

134.3 ± 20.1

127.2 ± 19.5

0.01

DBP (mmHg)

83.2 ± 12.0

77.4 ± 10.5

0.01

No. AHM

1.55 ± 1.23

1.48 ± 1.15

NS

USR (mmol/day)

52.7 ± 69.2

49.9 ± 72.1

NS

PSR (mmol/day)

86.8 ± 43.2

86.2 ± 49.7

NS

TSR (mmol/day)

139.4 ± 69.1

136.2 ± 64.8

NS

Na (mmol/L)

137.3 ± 4.4

135.1 ± 3.9

.01

Hematocrit (%)

34.0 ± 6.5

34.9 ± 5.8

NS

Albumin (g/dL)

3.49 ± 0.34

3.52 ± 0.27

NS

Icodextrin usage (%)

67.7% (21/31)

70.9% (22/31)

NS

ESA usage (%)

54.8% (17/31)

61.2% (19/31)

NS

ECW: Extracellular water, ICW: Intracellular water, TBW: Total body water, SBP: Systolic blood pressure,
DBP: Diastolic blood pressure, No.AHM: Number of antihypertensive medications, USR: Urinary sodium
removal, PSR: Peritoneal sodium removal, TSR: Total sodium removal, Na: Plasma sodium concentration, ESA:
Erythropoietin stimulating agent

Despite the multifactorial nature of hypertension,
volume overload clearly has the major role in PD patients
(15,16). Earlier studies have reported good volume and
blood pressure control in early periods of PD therapy; but
they also pointed out that the progressive loss of residual
renal function in following years could induce hypervolemia
and hypertension in these patients (17,18). Even though
hypervolemia is generally accepted as a result of inadequate
fluid removal in PD patients, a recent study showed that
hypertensive PD patients had a higher fluid and sodium
removal compared to normotensive ones and the authors
stressed the role of sodium intake along with inadequate
fluid removal in hypervolemia (19). Accordingly, reduced
salt intake was found to be associated with a decline in
blood pressure levels in PD patients (20). Gunal et al. put
their patients on a strict salt restriction and stopped all
antihypertensive treatments in 78 PD patients and showed
significantly reduced body weight and blood pressure levels
(6). In the present study, in addition to demonstration of
decreased blood pressure levels, a decrease in total body
water was also demonstrated with salt restriction.

Since fluid and salt removal usually reflect their amount
of intake, higher fluid and salt removal likely mean that too
much is ingested by the patients. Restricting fluid and salt
intake is suggested as the safest strategy to maintain good
fluid balance, which may decrease the dialysis dose and
the need for hypertonic solutions, as well as blood pressure
levels. However, according to our clinical practice, patients
with a longer duration of therapy seem to be more resistant
to dietary modifications.
The daily intake of sodium has been recommended
as less than 2.3 g/day (approximately 5.5 g/day salt) by
European Best Practice Guidelines at the initiation of PD
treatment (11). However, the SALTURK study showed that
daily salt consumption was approximately 18 g/day (daily
urinary sodium excretion was 308.3 ± 143.1 mmol/day) in
the general Turkish population (21). In a recent study from
Turkey on 373 chronic kidney disease patients from stages
1–5, average daily salt intake was reported as nearly 10 g/
day (22). In spite of strict dietary consultations, our results
were not very different. Average TSR, which reflects daily
salt consumption, was calculated as approximately 8 g/day
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Table 3. Comparison of body fluid status, blood pressure, sodium removal, and plasma sodium concentrations
of the hypertensive patients (n: 17) subgroup between the first and last visits.
First visit

Last visit

P

ECW (L)

19.0 ± 4.4

18.3 ± 3.5

0.04

ECW (%)

24.4 ± 2.5

23.8 ± 2.7

NS

ICW (L)

22.8 ± 6.5

22.5 ± 6.2

NS

ICW (%)

24.4 ± 2.5

23.8 ± 2.7

NS

TBW (L)

44.2 ± 12.3

42.8 ± 10.7

0.05

SBP (mmHg)

150.0 ± 9.5

142.1 ± 11.2

0.01

DBP (mmHg)

92.1 ± 6.1

85.0 ± 5.6

0.01

No. AHM

2.3 ± 0.9

2.2 ± 0.8

NS

USR (mmol/day)

67.1 ± 84.4

63.2 ± 89.5

NS

PSR (mmol/day)

97.2 ± 41.4

91.0 ± 48.9

NS

TSR (mmol/day)

164.3 ± 70.9

154.2 ± 72.3

NS

Na (mmol/L)

136.4 ± 3.9

134.0 ± 3.7

0.03

Icodextrin usage (%)

76.5% (13/17)

82.4% (14/17)

NS

ESA usage (%)

64.7% (11/17)

64.7% (11/17)

NS

ECW: Extracellular water, ICW: Intracellular water, TBW: Total body water, SBP: Systolic blood pressure,
DBP: Diastolic blood pressure, No.AHM: Number of antihypertensive medications, USR: Urinary sodium
removal, PSR: Peritoneal sodium removal, TSR: Total sodium removal, Na: Plasma sodium concentration, ESA:
Erythropoietin stimulating agent

for the total group and 9.1 g/day for the hypertensive PD
patient subgroup.
On the other hand, Dong et al. demonstrated that very
low sodium intake is accompanied by deficient protein and
energy intake, which is found to be related to increased
mortality in PD patients. In this study, the average daily salt
consumption was 1.41 g/day for low salt consumers and
2.47 g/day for high salt consumers (23). Obviously, daily
salt consumption of those patients was much lower than
our patients’ daily salt intake. This study suggests avoiding
malnutrition while targeting strict salt restriction.
There are some limitations of our study. Firstly,
although it was a prospective study, the follow-up time was

somewhat short and the sample size was small. Secondly,
we were unable to persuade all patients to restrict salt
intake as we had planned. It is likely that the changes in
the adherence also contributed to the decreased blood
pressure levels.
In conclusion, we want to underline that patients’
education about hypertension, hypervolemia, and
reduction of salt intake should be the main goals in
the therapy of patients with PD, in order to decrease
cardiovascular morbidity and mortality associated with
hypertension.
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